Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ticarcillin is a semisynthetic, extended-spectrum carboxypenicillin antibiotic belonging to the beta-lactam class. It is primarily used for the treatment of moderate-to-severe infections caused by susceptible Gram-negative bacteria, especially Pseudomonas aeruginosa and Proteus vulgaris. Its mechanism of action involves inhibition of bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby preventing cross-linking of peptidoglycan chains during cell division, which leads to bacterial cell lysis and death. Like other penicillins, it contains a β-lactam ring that can be hydrolyzed by β-lactamases produced by resistant bacteria[1][2][3][5]. Ticarcillin is not absorbed orally and must be administered intravenously or intramuscularly[3]. It has also been used in molecular biology as an alternative to ampicillin for selection purposes due to its stability in culture media[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ticarcillin.